Literature DB >> 2351482

Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma.

J Ishikawa1, S Maeda, K Umezu, T Sugiyama, S Kamidono.   

Abstract

We examined 22 cases of renal-cell carcinoma (RCC) for structural alterations of the epidermal growth factor receptor (EGFR) gene and found gene amplification in one case of high-stage-high-grade RCC. Dot blot analysis of the total RNA from tumorous and normal kidney tissues revealed overexpression of the EGFR gene in 12 of 20 (60%) cases of RCC. The highest expression was observed in the gene-amplified case. No correlation was observed between the level of EGFR mRNA and tumor stage or grade. Northern blot analysis revealed normal 10- and 5.6-kb EGFR mRNA bands in RCC. Our data indicate that gene amplification of the EGFR gene is one of the molecular mechanisms of its overexpression in a subset of RCCs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2351482     DOI: 10.1002/ijc.2910450606

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting.

Authors:  Michael J Grieco; H M C Shantha Kumara; Raymond Baxter; Nadav Dujovny; Matthew F Kalady; Vesna Cekic; Martin Luchtefeld; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-03-31       Impact factor: 4.584

Review 2.  Vaccine strategies for glioblastoma: progress and future directions.

Authors:  Christopher Jackson; Jacob Ruzevick; Henry Brem; Michael Lim
Journal:  Immunotherapy       Date:  2013-02       Impact factor: 4.196

3.  Potential roles of Centipede Scolopendra extracts as a strategy against EGFR-dependent cancers.

Authors:  Weina Ma; Dongdong Zhang; Lei Zheng; Yingzhuan Zhan; Yanmin Zhang
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

4.  Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.

Authors:  J M Boer; W K Huber; H Sültmann; F Wilmer; A von Heydebreck; S Haas; B Korn; B Gunawan; A Vente; L Füzesi; M Vingron; A Poustka
Journal:  Genome Res       Date:  2001-11       Impact factor: 9.043

5.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma.

Authors:  H Moch; P Schraml; L Bubendorf; M Mirlacher; J Kononen; T Gasser; M J Mihatsch; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 6.  The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.

Authors:  Rebecca G Pomerantz; Jennifer Rubin Grandis
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

7.  Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy.

Authors:  B Ljungberg; M Gåfvels; J E Damber
Journal:  Urol Res       Date:  1994

Review 8.  The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology.

Authors:  Fenghua Zeng; Amar B Singh; Raymond C Harris
Journal:  Exp Cell Res       Date:  2008-08-19       Impact factor: 3.905

9.  Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.

Authors:  Beverly Drucker; Jennifer Bacik; Michelle Ginsberg; Stephanie Marion; Paul Russo; Madhu Mazumdar; Robert Motzer
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

10.  Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma.

Authors:  Yeong-Shiau Pu; Chao-Yuan Huang; Yi-Zih Kuo; Wang-Yi Kang; Guang-Yaw Liu; A-Mei Huang; Hong-Jeng Yu; Ming-Kuen Lai; Shu-Pin Huang; Wen-Jeng Wu; Shean-Jaw Chiou; Tzyh-Chyuan Hour
Journal:  J Biomed Sci       Date:  2009-09-12       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.